[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JP6513404B2 - Fat burning promoter and hypothermia improving agent - Google Patents

Fat burning promoter and hypothermia improving agent Download PDF

Info

Publication number
JP6513404B2
JP6513404B2 JP2015001275A JP2015001275A JP6513404B2 JP 6513404 B2 JP6513404 B2 JP 6513404B2 JP 2015001275 A JP2015001275 A JP 2015001275A JP 2015001275 A JP2015001275 A JP 2015001275A JP 6513404 B2 JP6513404 B2 JP 6513404B2
Authority
JP
Japan
Prior art keywords
ucp1
hypothermia
extract
brown
extraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015001275A
Other languages
Japanese (ja)
Other versions
JP2016124842A (en
Inventor
知大 松本
知大 松本
高木 寛
寛 高木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Menard Cosmetic Co Ltd
Original Assignee
Nippon Menard Cosmetic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Menard Cosmetic Co Ltd filed Critical Nippon Menard Cosmetic Co Ltd
Priority to JP2015001275A priority Critical patent/JP6513404B2/en
Publication of JP2016124842A publication Critical patent/JP2016124842A/en
Application granted granted Critical
Publication of JP6513404B2 publication Critical patent/JP6513404B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

本発明は、パッションフラワー抽出物を含有することを特徴とする脂肪燃焼促進剤及び低体温改善剤に関する。 The present invention relates to a fat combustion promoter and a hypothermia improving agent characterized by containing passionflower extract.

脂肪組織は、生体に存在する重要な臓器の一つであり、白色脂肪組織と褐色脂肪組織の2つのタイプに大別される。白色脂肪組織は、主にエネルギーを中性脂肪として細胞内に貯蓄する白色脂肪細胞から構成されており、生体内の余剰エネルギーを蓄える働きがある。また、この細胞は、運動や飢餓時等、生体がエネルギーを必要とする際に、貯蓄した中性脂肪を遊離脂肪酸へと分解し、ミトコンドリアに存在する電子伝達系を介してアデノシン3リン酸(ATP)を合成することで、エネルギーを生体へ補給する役割を担っている。 Adipose tissue is one of the important organs present in the living body, and is roughly divided into two types, white adipose tissue and brown adipose tissue. White adipose tissue is mainly composed of white adipocytes that store energy as neutral fat in cells and has a function to store surplus energy in the living body. In addition, when the living body needs energy, such as during exercise or starvation, these cells break down the stored neutral fat into free fatty acids, and via adenosine's triphosphate via the electron transport system present in mitochondria. By synthesizing ATP, it plays a role of supplying energy to the living body.

一方、褐色脂肪組織は主に褐色脂肪細胞で構成されている。白色脂肪細胞と同様に細胞内に中性脂肪を貯蓄するが、脱共役タンパク質1(UCP1:uncoupling protein 1)の働きにより、電子伝達系におけるATP合成を経ずに、中性脂肪を熱へと変換する。この熱変換は、過剰に摂取したエネルギーを消費することで生体内の中性脂肪量を調節する役割を担っている(非特許文献1〜3)。また、白色脂肪細胞との違いとして、ペルオキシソーム増殖因子活性化受容体ガンマ活性化補助因子1α(PGC1α:peroxisome proliferator−activated receptor gamma coactivator 1−alpha)、細胞死活性化因子CIDE−A(CIDEA:cell death activator CIDE−A)、ピルビン酸脱水素酵素アイソザイム4(PDK4:pyruvate dehydrogenase kinase isozyme 4)が特異的に発現することが知られている(非特許文献4)。 On the other hand, brown adipose tissue is mainly composed of brown adipocytes. Like white fat cells, neutral fat is stored in cells, but due to the function of uncoupling protein 1 (UCP1), neutral fat is transferred to heat without undergoing ATP synthesis in the electron transfer system. Convert. This heat conversion plays a role of regulating the amount of neutral fat in the living body by consuming the energy which has been ingested in excess (Non-patent documents 1 to 3). Moreover, as a difference from white fat cells, peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC1 alpha: peroxisome proliferator-activated receptor gamma coactivator 1-alpha), cell death activator CIDE-A (CIDEA: cell) It is known that death activator CIDE-A) and pyruvate dehydrogenase isozyme 4 (PDK4: pyruvate dehydrogenase kinase isozyme 4) are specifically expressed (Non-patent Document 4).

これら白色脂肪細胞と褐色脂肪細胞の働きによって生体内の中性脂肪量のバランスが保たれているが、エネルギーの過剰摂取により白色脂肪組織に中性脂肪が必要以上に蓄積することで肥満が生じ、これがメタボリックシンドローム発症の主な原因として考えられている(非特許文献5、6)。 Although the balance of neutral fat content in the living body is maintained by the function of these white fat cells and brown fat cells, excess intake of energy causes excess fat accumulation in white fat tissue, resulting in obesity This is considered to be the main cause of the onset of the metabolic syndrome (Non-patent Documents 5 and 6).

肥満やメタボリックシンドロームを改善するにはエネルギーを効率的に消費する必要がある。そのため、エネルギー消費を行う褐色脂肪細胞に着目した研究は年々増加しており、ジェニパー油や共役リノール酸による褐色脂肪組織の重量増加(特許文献1、2)、わさび含有成分による褐色脂肪細胞におけるUCP1の発現亢進(特許文献3)等が知られている。 It is necessary to consume energy efficiently to improve obesity and metabolic syndrome. Therefore, research focusing on brown adipocytes that consume energy is increasing year by year, and the weight gain of brown adipose tissue by genipa oil and conjugated linoleic acid (patent documents 1 and 2), UCP 1 in brown adipocytes by components containing wasabi wasp The upregulation of expression (Patent Document 3) and the like are known.

一方、近年の研究成果として、白色脂肪細胞が寒冷刺激、β3アドレナリン受容体を介した応答、あるいは運動により誘導されるホルモンであるアイリシンによって、褐色脂肪細胞と類似のUCP1を発現する性質をもった細胞になることが確認されている(非特許文献7、8)。そのため、肥満やメタボリックシンドロームの改善に対して、褐色脂肪細胞の増加及びUCP1の発現を亢進させる作用ばかりではなく、白色脂肪細胞の中性脂肪をエネルギーとして消費させる作用の両方の作用をもった素材を見つけだすことができれば、より高い効果が期待できる。 On the other hand, as a result of recent researches, white fat cells have the property of expressing UCP1 similar to brown fat cells by cold stimulation, response via β3 adrenergic receptor, or iricin which is a hormone induced by exercise. It has been confirmed that they become cells (Non-patent Documents 7 and 8). Therefore, it has not only the effect of enhancing brown adipocytes and the expression of UCP1 but also the effect of consuming white fat neutral fat as energy for improving obesity and metabolic syndrome. If you can find out, you can expect higher effects.

ヒト等の恒温動物の体温は、恒常性(ホメオスタシス)により一定範囲内に保たれている。体温は環境との関係でふたつに大別され、環境温度の影響を受けにくい身体深部の温度を深部体温、影響を受けやすい表層の温度を体表面温という。深部体温は体表面温と異なり体温調節により一定に調節されており、一般的に直腸温、口腔温、腋窩温、鼓膜温を体温計で測定する。一方で、体表面温は身体の外層部の温度であり、環境温度によって変化する。体表面温はサーモグラフィー等を用いて測定する。 The body temperature of a homeothermic animal such as a human being is kept within a certain range by homeostasis. Body temperature is roughly divided into two in relation to the environment, the temperature at the deep part of the body that is not easily influenced by the environmental temperature is called the core body temperature, and the temperature of the susceptible surface is called the body surface temperature. Unlike body surface temperature, core temperature is constantly regulated by thermoregulation, and generally, rectum temperature, oral temperature, axillary temperature and tympanic temperature are measured with a thermometer. On the other hand, the body surface temperature is the temperature of the outer layer of the body, and changes with the environmental temperature. Body surface temperature is measured using thermography or the like.

不規則な生活や過度なストレスによる基礎代謝量の低下や低温環境の影響により、深部体温が低下した低体温に陥る。低体温になると、悪寒、不快感、免疫力低下、冷え等様々な身体機能への支障が生じる。低体温の改善方法として、高麗人参、生姜等血流を促進させる方法、マッサージにより血行を促進させる方法、温かい飲食物の摂取や入浴等の方法が提案されているものの、それらの方法は体表面温を一過的に上昇させるのみであり、深部体温を上昇させることはできないことから、根本的な低体温の改善には至っていない(特許文献4、5)。 Due to irregular living and excessive stress, the decrease in basal metabolic rate and the influence of low temperature environment lead to hypothermia with decreased core body temperature. Hypothermia causes various physical functions such as chills, discomfort, decreased immunity, and cold. Methods to improve blood flow such as ginseng and ginger, methods to promote blood circulation by massage, and methods such as intake of warm food and bathing have been proposed as methods to improve hypothermia, but those methods are body surface Since it only raises the temperature transiently and can not raise core body temperature, it has not resulted in the improvement of the fundamental hypothermia (patent documents 4 and 5).

褐色脂肪細胞の役割の一つとして体温維持があり、主に動物の冬眠時や新生児が身体を震わせずに熱を産生するために働く。一方で、UCP1の発現亢進に伴い深部体温が上昇することや、低温暴露や麻酔等により低体温になった際の回復時に褐色脂肪細胞が活性化することが確認されている(非特許文献9〜11)。そのため、褐色脂肪細胞に働きかけて熱産生を増加させることは、低体温の改善に有効であるといえる。 One of the roles of brown adipocytes is maintenance of body temperature, which mainly works during hibernation of animals and newborns to produce heat without shaking their bodies. On the other hand, it has been confirmed that core body temperature rises with the increase of UCP1 expression, and brown adipocytes are activated at the time of recovery when hypothermia is caused by low temperature exposure or anesthesia etc. (Non-patent document 9) ~ 11). Therefore, it can be said that acting on brown adipocytes to increase heat production is effective in improving hypothermia.

深部体温の上昇を目的として褐色脂肪組織の交感神経活動を上昇させる組成物(特許文献6)が検討されている。しかしながら、従来の技術においては、褐色脂肪細胞における熱産生に寄与するUCP1を増加させるのみである。本発明で提案するような白色脂肪細胞においてもUCP1を増加させることで、より高い低体温改善効果が期待できる。 The composition (patent document 6) which raises the sympathetic nerve activity of brown adipose tissue for the purpose of a rise in core body temperature is examined. However, the prior art only increases UCP1 which contributes to thermogenesis in brown adipocytes. Even in white fat cells as proposed in the present invention, a higher hypothermia improvement effect can be expected by increasing UCP1.

パッションフラワーは、ブラジル原産のトケイソウ科(Passifloraceae)の植物で、学名をパスシフロラ インカルナタ(Passiflora incarnata)といい、薬草として利用されるのは主にincarnata種(チャボトケイソウ)、edulis種(クダモノトケイソウ)の葉、蔓、幹の部分で、主な成分は、多糖体とアルカノイド類を含むフラボノイドである。パッションフラワーの主な薬効として、鎮静、精神安定、糖化阻害作用等が知られている(特許文献7、8)。また、幹細胞から褐色脂肪細胞への分化促進作用も知られているが(特許文献9)、生体内における褐色脂肪組織重量の増加や白色脂肪細胞におけるUCP1発現亢進作用は未だ知られていない。 Passionflower is a plant of the family Passifloraceae native to Brazil, and its scientific name is called Passiflora incarnata (Passiflora incarnata), and it is mainly used as herbs that it is of the incarnata species (Cabort diatoma), edulis species (Buda monotonicho) The main components of leaves, branches and stems are flavonoids including polysaccharides and alkanoids. As the main medicinal effects of passionflower, sedation, mental stability, glycation inhibition and the like are known (Patent Documents 7 and 8). In addition, differentiation promoting action from stem cells to brown adipocytes is also known (Patent Document 9), but the increase in brown adipose tissue weight in vivo and UCP1 expression enhancing action in white adipocytes are not known yet.

特許第3951271号公報Patent No. 3951271 gazette 特許第3207823号公報Patent No. 3207823 特開2006−328056号公報Unexamined-Japanese-Patent No. 2006-328056 特開2003−40788号公報Japanese Patent Application Publication No. 2003-40788 特開2007−145773号公報JP, 2007-145773, A 特開2014−15430号公報JP, 2014-15430, A 特開2002−101850号公報JP 2002-101850 A 特開2008−088102号公報Patent Document 1: Japanese Patent Application Publication No. 2008-088102 特開2013−151437号公報JP, 2013-151437, A 審良静男,医学のあゆみ,1998,184,513−517Shizuka Akira, History of Medicine, 1998, 184, 513-517 斉藤昌之,肥満の科学,第124回日本医学会シンポジウム,62−70Saito, Masayuki, Science of Obesity, The 124th Japan Medical Association Symposium, 62-70 香川靖雄,医学のあゆみ,1998,184,529−533Yoshio Kagawa, History of Medicine, 1998, 184, 529-533 Jun,Wu.,et al.,Cell,2012,150,366−376Jun, Wu. , Et al. , Cell, 2012, 150, 366-376. 青木茂久ら,日本臨床,2006,64巻,増刊9,175−179Shigeru Aoki et al., Japan Clinical Clinic, 2006, volume 64, special issue 9, 175-179 小川佳宏ら,実験医学,2007,25,増刊15,54−60Akihiro Ogawa et al., Experimental Medicine, 2007, 25, Special Issue 15, 54-60 入江由希子ら,肥満研究,2007,7,1,63−65Irie Yukiko et al., Obesity Research, 2007, 7, 1, 63-65 Bostrom,P.,et al.,Nature、2012、481、463−468Bostrom, P .; , Et al. , Nature, 2012, 481, 463-468 Kengo,Azushima.,et al.,PLOS ONE、2013、8、10Kengo, Azushima. , Et al. , PLOS ONE, 2013, 8, 10 Bin,Feng.,et al.,Ann.N.Y.Acad.Sci、2013、1281、160−177Bin, Feng. , Et al. , Ann. N. Y. Acad. Sci, 2013, 1281, 160-177 Shimizu,Y.,et al.,Am.J.Physiol、2013、1281、160−177Shimizu, Y. , Et al. , Am. J. Physiol, 2013, 1281, 160-177

本発明の目的は、褐色脂肪細胞及び白色脂肪細胞における脂肪燃焼を促進することにより、肥満、メタボリックシンドロームや低体温を改善することができる、日常的に服用可能で安全性の高い脂肪燃焼促進剤及び低体温改善剤を提供することである。 It is an object of the present invention to provide a routinely available and highly safe fat burning promoter that can improve obesity, metabolic syndrome and hypothermia by promoting fat burning in brown fat cells and white fat cells. And providing a hypothermia improving agent.

本発明者らは、上記課題を解決すべく鋭意研究した結果、パッションフラワー抽出物が褐色脂肪細胞への分化促進、褐色脂肪組織の重量増加、褐色脂肪細胞及び白色脂肪細胞におけるUCP1発現亢進によって、脂肪燃焼促進効果及び低体温改善効果を示すことを見出し、本発明を完成するに至った。 As a result of intensive studies to solve the above problems, the present inventors have found that passionflower extract promotes differentiation into brown adipocytes, increased weight of brown adipose tissue, and enhanced UCP1 expression in brown adipocytes and white adipocytes. The inventors have found that they exhibit a fat combustion promoting effect and a hypothermia improving effect, and have completed the present invention.

本発明に用いるパッションフラワー抽出物は、パッションフラワーの葉、蔓、幹、茎、果実、花から溶媒で抽出することによって得られるが、全草を用いることが望ましい。その抽出方法は特に限定されず、加熱抽出であっても、常温抽出であってもよい。 The passionflower extract used in the present invention is obtained by extraction with a solvent from passionflower leaves, anthers, stems, stems, fruits and flowers, but it is preferable to use whole grass. The extraction method is not particularly limited, and it may be heat extraction or normal temperature extraction.

パッションフラワーの抽出に用いる溶媒としては、例えば、水、低級アルコール類(メタノール、エタノール、1−プロパノール、2−プロパノール、1−ブタノール、2−ブタノール等)、液状多価アルコール(1,3−ブチレングリコール、プロピレングリコール、グリセリン等)、ケトン類(アセトン、メチルエチルケトン等)、アセトニトリル、エステル類(酢酸エチル、酢酸ブチル等)、炭化水素類(ヘキサン、ヘプタン等)、エーテル類(エチルエーテル、テトラヒドロフラン、プロピルエーテル、ポリオキシエチレンセチルエーテル等)が挙げられるが、好ましくは、水、低級アルコール等の極性溶媒であり、より好ましくは、水、エタノール、および水とエタノールの混合溶媒である。これらの溶媒は一種でも二種以上を混合して用いてもよい。また、これらの有機溶媒で抽出する際には抽出効率を上げるために、例えば界面活性剤、酵素製剤(ペクチナーゼ、セルラーゼ、プロテアーゼ等)等の添加物を本発明の効果を損なわない範囲で抽出溶媒に加えてもよい。 As a solvent used for extraction of passion flower, for example, water, lower alcohols (methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, etc.), liquid polyhydric alcohol (1,3-butylene, etc.) Glycol, propylene glycol, glycerin etc., ketones (acetone, methyl ethyl ketone etc.), acetonitrile, esters (ethyl acetate, butyl acetate etc.), hydrocarbons (hexane, heptane etc.), ethers (ethyl ether, tetrahydrofuran, propyl) Ether, polyoxyethylene cetyl ether and the like) can be mentioned, preferably polar solvents such as water and lower alcohols, and more preferably water, ethanol, and a mixed solvent of water and ethanol. These solvents may be used alone or in combination of two or more. In addition, when extracting with these organic solvents, in order to increase extraction efficiency, additives such as surfactants, enzyme preparations (pectinase, cellulase, protease, etc.) can be used as extraction solvents as long as the effects of the present invention are not impaired. You may add to

抽出溶媒として水とアルコール類の混合溶媒を使用する場合は、アルコール濃度が10〜90%とすることが好ましい。具体的には、エタノール濃度が20〜70%の含水エタノール、1,3−ブチレングリコール濃度が20〜70%の含水1,3−ブチレングリコール等の溶媒が好適に使用され、エタノール濃度が30〜60%の含水エタノールの使用が特に好ましい。 When using the mixed solvent of water and alcohol as an extraction solvent, it is preferable to make alcohol concentration into 10 to 90%. Specifically, a solvent such as water-containing ethanol having an ethanol concentration of 20 to 70%, and water-containing 1,3-butylene glycol having a concentration of 20 to 70% of 1,3-butylene glycol is suitably used, and the ethanol concentration is 30 to 30 The use of 60% hydrous ethanol is particularly preferred.

抽出に使用する溶媒量は、抽出原料1重量部に対して通常2〜200重量部、好ましくは10〜100重量部である。抽出溶媒量がこの範囲を下回ると、抽出原料全体に抽出溶媒が行き渡らず、抽出効率が低下する可能性があり、抽出溶媒量がこの範囲を超えると、後に抽出溶媒除去を行う際の負担が増加する。 The amount of solvent used for extraction is usually 2 to 200 parts by weight, preferably 10 to 100 parts by weight, per 1 part by weight of the extraction raw material. If the amount of extraction solvent falls below this range, the extraction solvent may not spread over the entire extraction raw material, and the extraction efficiency may decrease, and if the amount of extraction solvent exceeds this range, the burden on removing the extraction solvent later is To increase.

抽出温度は、抽出に使用する溶媒の沸点以下の温度であり、特に限定されず、例えば加熱抽出であってもよいし、常温抽出であってもよい。 The extraction temperature is a temperature equal to or lower than the boiling point of the solvent used for extraction, and is not particularly limited. For example, it may be heat extraction or normal temperature extraction.

抽出時間は、常温抽出の場合は1〜2週間、加熱抽出の場合は30分間〜24時間、好ましくは1〜10時間であるが、抽出溶媒の種類、抽出温度等の条件によって適宜調節できる。抽出操作の回数は特に限定されるものではなく、1回であってもよいし、1回目の抽出後に再度新鮮な抽出溶媒を添加し、2回目以降の抽出操作を行なってもよい。また、同一の抽出溶媒を用いて複数回抽出操作を行ってもよい。 The extraction time is 1 to 2 weeks in the case of cold extraction, and 30 minutes to 24 hours, preferably 1 to 10 hours in the case of heat extraction, but can be appropriately adjusted according to conditions such as the type of extraction solvent and extraction temperature. The number of extraction operations is not particularly limited, and may be one, or after the first extraction, fresh extraction solvent may be added again to perform the second and subsequent extraction operations. Moreover, you may perform extraction operation in multiple times using the same extraction solvent.

抽出方法は、当分野で通常用いられる方法であればよく、室温又は加熱下で、任意の装置を使用して行う。具体的には、抽出溶媒を満たした抽出処理槽に抽出原料を投入し、必要に応じて時々攪拌しながら可溶性成分を溶出した後、濾過して残渣を除去し、抽出物を得る。 The extraction method may be any method commonly used in the art, and is performed using any apparatus at room temperature or under heating. Specifically, the extraction raw material is charged into an extraction treatment tank filled with an extraction solvent, and the soluble components are eluted while stirring occasionally as necessary, and then the residue is removed by filtration to obtain an extract.

上記抽出物は、抽出した溶液のまま用いてもよく、必要に応じて、その効果に影響のない範囲で更に、濃縮、希釈、濾過、活性炭等による脱色、脱臭、エタノール沈殿等の処理をして用いてもよい。さらには、抽出した溶液を濃縮乾固、噴霧乾燥、凍結乾燥等の処理を行い、乾燥物として用いてもよい。 The above-mentioned extract may be used as it is in the extracted solution, and if necessary, it may be further subjected to processing such as concentration, dilution, filtration, decolorization with activated carbon, deodorization, ethanol precipitation, etc. You may use it. Furthermore, the extracted solution may be subjected to treatments such as concentration to dryness, spray drying, lyophilization and the like, and used as a dried product.

本発明に関わる脂肪燃焼促進剤及び低体温改善剤には、発明の効果を損なわない範囲において、生薬、ビタミン、ミネラル、アミノ酸等の他に、乳糖、デンプン、セルロース、マルチトール、デキストリン等の賦形剤、グリセリン脂肪酸エステル、ショ糖脂肪酸エステル等の界面活性剤、ゼラチン、プルラン、シェラック、ツェイン等の被膜剤、小麦胚芽油、米胚芽油、サフラワー油等の油脂類、ミツロウ、米糠ロウ、カルナウバロウ等のワックス類、ショ糖、ブドウ糖、果糖、ステビア、サッカリン、スクラロース等の甘味料、並びにクエン酸、リンゴ酸、グルコン酸等の酸味料等を適宜含有することができる。生薬としては、高麗人参、アメリカ人参、田七人参、プロポリス、アガリクス、ブルーベリー、アイブライト、イチョウ葉及びその抽出物等が挙げられる。ビタミンとしては、ビタミンA、D、E、K等の油溶性ビタミン、ビタミンB1、B2、B6、B12、C、ナイアシン、パントテン酸、葉酸、ビオチン等の水溶性ビタミンが挙げられる。また、アミノ酸ではL−カルニチン、L−シトルリン、L−オルニチン等も挙げられる。 The fat combustion promoting agent and hypothermia improving agent according to the present invention may be added with lactose, starch, cellulose, maltitol, dextrin, etc. in addition to crude drugs, vitamins, minerals, amino acids etc. insofar as the effects of the invention are not impaired. Additive, surfactant such as glycerin fatty acid ester, sucrose fatty acid ester, coating agent such as gelatin, pullulan, shellac, zein, oil such as wheat germ oil, rice germ oil, safflower oil, beeswax, rice bran wax, Waxes such as carnauba wax, sucrose, glucose, fructose, sweeteners such as stevia, saccharin and sucralose, and acidulants such as citric acid, malic acid and gluconic acid can be suitably contained. Examples of the herbal medicine include ginseng, American ginseng, rice field ginseng, propolis, agaricus, blueberries, eye blight, ginkgo biloba and extracts thereof and the like. Examples of vitamins include oil-soluble vitamins such as vitamin A, D, E and K, and water-soluble vitamins such as vitamins B1, B2, B6, B12, C, niacin, pantothenic acid, folic acid and biotin. Moreover, L-carnitine, L-citrulline, L-ornithine etc. are mentioned by an amino acid.

本発明に関わるパッションフラワー抽出物の摂取量は、形態、症状、年齢、体重等に応じて適宜決定することができる。例えば、成人に経口投与する場合には、一日の投与量は1〜1000mg、好ましくは5〜500mg、特に好ましくは10〜100mgである。 The intake of the passionflower extract according to the present invention can be appropriately determined according to the form, symptoms, age, body weight and the like. For example, when orally administered to adults, the daily dose is 1 to 1000 mg, preferably 5 to 500 mg, particularly preferably 10 to 100 mg.

本発明に関わる脂肪燃焼促進剤及び低体温改善剤は、医薬品、医薬部外品、又は食品のいずれにも用いることができる。投与方法としては、経口投与(内服剤)及び経皮投与(外用剤)等が挙げられるため、製剤形態は種々のものを選択できるが、特に内服剤が好ましい。例えば、散剤、顆粒剤、錠剤、糖衣錠剤、カプセル剤、シロップ剤、丸剤、懸濁剤、液剤、乳剤等の通常の医薬品の形態、飲料、ガム、チョコレート、飴、麺、パン、ケーキ、ビスケット、羊羹、ゼリー、缶詰、レトルト食品、畜肉食品、水産練食品、マーガリン、バター、マヨネーズ等の通常の食品の形態を採用することができる。中でも、摂取量を調節しやすい飲料、カプセル剤、錠剤、顆粒剤等が好ましい。外用剤としては、ローション、クリーム、乳液、浴用剤、注射薬、座薬等の剤型が挙げられる。 The fat combustion promoting agent and hypothermia improving agent according to the present invention can be used in any of pharmaceuticals, quasi drugs, and foods. The method of administration includes oral administration (internal use) and transdermal administration (external use) and the like, so various dosage forms can be selected, and in particular, internal use is preferable. For example, common pharmaceutical forms such as powders, granules, tablets, coated tablets, capsules, syrups, pills, suspensions, solutions, emulsions, etc., beverages, gums, chocolate, candy, noodles, bread, cakes, Common food forms such as biscuits, mutton, jellies, canned, retort foods, meat and meat foods, seafood foods, margarines, butter, mayonnaise and the like can be adopted. Among them, beverages, capsules, tablets, granules and the like which can be easily adjusted in intake amount are preferable. The external preparations include dosage forms such as lotions, creams, emulsions, bath preparations, injections and suppositories.

本発明によれば、褐色脂肪細胞への分化促進、褐色脂肪組織の重量増加、褐色脂肪細胞及び白色脂肪細胞におけるUCP1発現亢進によって脂肪燃焼促進効果及び低体温改善効果を発揮する脂肪燃焼促進剤及び低体温改善剤を提供することができる。 According to the present invention, a fat burn promoting agent that exerts a fat burn promoting effect and a hypothermia improving effect by promoting differentiation into brown fat cells, increasing weight of brown fat tissue, enhancing UCP1 expression in brown fat cells and white fat cells A hypothermia improving agent can be provided.

本発明を詳細に説明するために実施例を挙げるが、本発明はこれに限定されるものではない。実施例に示す含有量の%は重量%を示す。 Although an example is given in order to explain the present invention in detail, the present invention is not limited to this. The% of the content shown in the examples indicates% by weight.

(製造例1)パッションフラワー30%エタノール抽出物
パッションフラワーの全草の乾燥物(フランス産)20gに、精製水560gとエタノール240gを加え、室温で1週間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してパッションフラワー30%エタノール抽出物を10.6g得た。
(Preparation Example 1) Passion Flower 30% Ethanol Extract Passion Flower 20 g of whole grass dried (from France) is added 560 g of purified water and 240 g of ethanol, extracted for 1 week at room temperature, filtered and the filtrate The solution was concentrated and lyophilized to give 10.6 g of passionflower 30% ethanol extract.

(製造例2)パッションフラワー60%エタノール抽出物
パッションフラワーの全草の乾燥物(フランス産)20gに、精製水320gとエタノール480gを加え、室温で1週間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してパッションフラワー60%エタノール抽出物を10.6g得た。
Production Example 2 Passion Flower 60% Ethanol Extract Passion Flower 20 g of whole grass dried product (from France), add 320 g of purified water and 480 g of ethanol, extract for 1 week at room temperature, filter, and filter the filtrate Concentrated and lyophilized to give 10.6 g of passionflower 60% ethanol extract.

(製造例3)パッションフラワー熱水抽出物
乾燥したパッションフラワーの茎と葉の混合物(フランス産)40gに、精製水800gを加え、95〜100℃で2時間抽出した。得られた抽出液を濃縮乾燥してパッションフラワー熱水抽出物を11.4g得た。
Production Example 3 Passionflower Hot Water Extract To 800 g of a mixture of dried passionflower stem and leaf (from France) was added 800 g of purified water, followed by extraction at 95 to 100 ° C. for 2 hours. The obtained extract was concentrated and dried to obtain 11.4 g of passionflower hot water extract.

(製造例4)パッションフラワーエタノール抽出物
パッションフラワーの果実の乾燥物(フランス産)20gに、エタノール800gを加え、室温で1週間抽出した後、濾過し、その濾液を濃縮し、凍結乾燥してパッションフラワーエタノール抽出物を2.4g得た。
Production Example 4 Passionflower Ethanol Extract To 800g of dried fruit (from France) of passionflower fruit, 800 g of ethanol is added and extracted for 1 week at room temperature, followed by filtration, and the filtrate is concentrated and lyophilized. 2.4 g of passionflower ethanol extract was obtained.

飲料1
<処方> 含有量(%)
1.パッションフラワー30%エタノール抽出物(製造例1) 0.05
2.アイブライト20%エタノール抽出物 0.05
3.L−カルニチン 1.0
4.マルチトール 8.0
5.クエン酸 0.35
6.香料 0.1
7.精製水で全量を100とする
<製造方法>
成分7に成分1〜6を加え、攪拌溶解して濾過し、加熱殺菌して100mLアルミ缶に充填する。
<用法>
本飲料を1日1本摂取する。
Beverage 1
<Prescription> Content (%)
1. Passion Flower 30% Ethanol Extract (Production Example 1) 0.05
2. Eye bright 20% ethanol extract 0.05
3. L-carnitine 1.0
4. Maltitol 8.0
5. Citric acid 0.35
6. Flavoring agent 0.1
7. Make the total amount 100 with purified water
<Manufacturing method>
Ingredients 1 to 6 are added to ingredient 7, stirred to dissolve, filtered, heat-sterilized and filled in a 100 mL aluminum can.
<Usage>
Take one bottle of this beverage daily.

飲料2
<処方> 含有量(%)
1.パッションフラワー60%エタノール抽出物(製造例2) 0.02
2.L−カルニチン 0.3
3.エリスリトール 8.0
4.クエン酸 0.3
5.香料 0.1
6.精製水で全量を100とする
<製造方法>
成分6に成分1〜5を加え、攪拌溶解して濾過し、加熱殺菌して100mLアルミ缶に充填する。
<用法>
本飲料を1日1本摂取する。
Beverage 2
<Prescription> Content (%)
1. Passion Flower 60% Ethanol Extract (Production Example 2) 0.02
2. L-carnitine 0.3
3. Erythritol 8.0
4. Citric acid 0.3
5. Flavoring agent 0.1
6. Make the total amount 100 with purified water
<Manufacturing method>
Ingredients 1 to 5 are added to ingredient 6, stirred, dissolved, filtered, heat-sterilized and filled in a 100 mL aluminum can.
<Usage>
Take one bottle of this beverage daily.

軟カプセル剤
<処方> 含有量(%)
1.パッションフラワー熱水抽出物(製造例3) 1.0
2.ひまわり油 90.0
3.ミツロウ 6.0
4.ビタミンE 3.0
<製造方法>
成分1〜4を混合し、ゼラチン、グリセリンで構成される被膜に、250mg充填し、乾燥後、軟カプセル剤を得る。
<用法>
1日当り4粒摂取する。
Soft Capsule <Formulation> Content (%)
1. Passion Flower Hot Water Extract (Production Example 3) 1.0
2. Sunflower oil 90.0
3. Bee wax 6.0
4. Vitamin E 3.0
<Manufacturing method>
Ingredients 1 to 4 are mixed, 250 mg is filled in a coating composed of gelatin and glycerin, and after drying, a soft capsule is obtained.
<Usage>
Ingest 4 tablets per day.

硬カプセル剤
<処方> 含有量(%)
1.パッションフラワーエタノール抽出物(製造例4) 5.0
2.馬鈴薯デンプン 92.0
3.ショ糖脂肪酸エステル 3.0
<製造方法>
成分1〜3を混合し、2号硬カプセルに250mg充填して硬カプセル剤を得る。
<用法>
1日当り4粒摂取する。
Hard capsule <prescription> Content (%)
1. Passion Flower Ethanol Extract (Production Example 4) 5.0
2. Potato starch 92.0
3. Sucrose fatty acid ester 3.0
<Manufacturing method>
Ingredients 1 to 3 are mixed, and 250 mg is filled in a No. 2 hard capsule to obtain a hard capsule.
<Usage>
Ingest 4 tablets per day.

錠剤
<処方> 含有量(%)
1.パッションフラワー30%エタノール抽出物(実施例1) 10.0
2.乳糖 60.0
3.還元麦芽糖水飴 20.0
4.結晶セルロース 5.0
5.グリセリン脂肪酸エステル 5.0
<製造方法>
成分1〜5を混合して打錠成型し、0.3gの錠剤を得る。
<用法>
1日当り3粒摂取する。
Tablet <prescription> Content (%)
1. Passion Flower 30% Ethanol Extract (Example 1) 10.0
2. Lactose 60.0
3. Reduced maltose starch syrup 20.0
4. Crystalline cellulose 5.0
5. Glycerin fatty acid ester 5.0
<Manufacturing method>
Ingredients 1 to 5 are mixed and pressed to obtain 0.3 g tablets.
<Usage>
Ingest 3 tablets per day.

比較例1 従来の飲料
実施例1の飲料において、パッションフラワー30%エタノール抽出物を水に置き換えたものを従来の飲料とした。
Comparative Example 1 In the beverage of the conventional beverage Example 1, the passionflower 30% ethanol extract was replaced with water to obtain a conventional beverage.

(実験例1)褐色脂肪細胞への分化促進作用の検討
ヒト皮下脂肪組織由来幹細胞(ZENBIO)を24ウェルプレートに5×10個播種して、細胞増殖培地で6日間培養した。パッションフラワー抽出物(製造例1〜4)を0.25mg/mLとなるように溶解させた白色脂肪細胞分化誘導培地に置換してから7日間培養し、遺伝子発現解析を行った。遺伝子発現解析は、褐色脂肪細胞で発現する遺伝子であるUCP1、PGC1α、CIDEA、PDK4の遺伝子発現変動をリアルタイムPCR法で評価した。対照群を1とした遺伝子発現量比を算出した。
(Experimental example 1) Examination of differentiation promoting effect to brown adipocytes Human subcutaneous adipose tissue-derived stem cells (ZENBIO) were seeded in 24 well plates at 5 × 10 5 and cultured in cell growth medium for 6 days. Gene expression analysis was carried out by culturing for 7 days after replacing the passion flower extract (Production Examples 1 to 4) with a white adipocyte differentiation induction medium dissolved to 0.25 mg / mL. The gene expression analysis evaluated the gene expression fluctuation | variation of UCP1, PGC1 alpha, CIDEA, and PDK4 which are genes expressed in brown fat cells by the real-time PCR method. The ratio of gene expression was calculated using the control group as 1.

細胞増殖培地は、25mM HEPES(同仁化学)、3% GLUTAMAX−1(GIBCO)、1% Insulin,Transferrin,Selenium,Ethanolamine Solution(GIBCO)、1% ウシ胎児血清(SIGMA、56℃で30分間加温して非動化したもの)、10ng/mL FGF−basic(PEPROTECH)、0.4μg/mL hydrocortison(WAKO)、1% Antibiotic,Antimycotic(GIBCO)となるように添加した50%αMEM(SIGMA)、50%DMEM(SIGMA)培地を使用した。 Cell growth medium: 25 mM HEPES (Dojin Chemical), 3% GLUTAMAX-1 (GIBCO), 1% Insulin, Transferrin, Selenium, Ethanolamine Solution (GIBCO), 1% fetal bovine serum (SIGMA, 30 minutes at 56 ° C.) , 10 ng / mL FGF-basic (PEPROTECH), 0.4 μg / mL hydrocortison (WAKO), 50% αMEM (SIGMA) added to become 1% Antibiotic, Antimycotic (GIBCO), 50% DMEM (SIGMA) medium was used.

白色脂肪細胞分化誘導培地は、1μM dexamethason(SIGMA)、0.5mM 3−isobutyl−1−methylxanthine(SIGMA)、0.2mM indomethacin(SIGMA)、10% ウシ胎児血清(SIGMA)、10μg/mL insulin(SIGMA)、33μM biotin(SIGMA)、1% Antibiotic,Antimycotic(GIBCO)となるように添加したDMEM(SIGMA)培地を使用した。 White adipocyte differentiation induction medium is 1 μM dexamethason (SIGMA), 0.5 mM 3-isobutyl-1-methylxanthine (SIGMA), 0.2 mM indomethacin (SIGMA), 10% fetal bovine serum (SIGMA), 10 μg / mL insulin ( SIGMA), 33 μM biotin (SIGMA), DMEM (SIGMA) medium supplemented to 1% Antibiotic, Antimycotic (GIBCO) was used.

褐色脂肪細胞発現遺伝子の発現量比の結果を表1に示す。パッションフラワー抽出物を添加すると、褐色脂肪細胞発現遺伝子であるUCP1、PGC1α、CIDEA、PDK4の遺伝子発現が亢進した。すなわち、パッションフラワー抽出物には褐色脂肪細胞への分化促進効果があることが示された。 Table 1 shows the results of the expression ratio of brown fat cell expressed genes. Addition of passionflower extract enhanced the gene expression of brown adipocyte-expressing genes UCP1, PGC1α, CIDEA, and PDK4. That is, it has been shown that the passionflower extract has an effect of promoting differentiation into brown fat cells.

(実験例2)肥満モデルマウスの褐色脂肪組織増加作用の検討
8週齢の雌性C57BL/6Jマウスを予備飼育した後、卵巣摘出を行うことで肥満モデルマウスを作製して未添加群とパッションフラワー抽出物(製造例1〜4)群に分けた。また、偽手術を行ったマウスを対照群として設けた。施術後から、表2に示す実験食を与えて、8週間飼育後、褐色脂肪組織を摘出して重量を測定した。各個体の体重あたりの褐色脂肪組織重量を算出し、評価した。
(Experimental example 2) Examination of brown fat tissue increasing action of obese model mice After preparing 8-week-old female C57BL / 6J mice for preliminary breeding, obese-extracted obese model mice are prepared and a non-added group and passion flower The extract (Production Examples 1 to 4) was divided into groups. In addition, mice subjected to a sham operation were provided as a control group. After the treatment, the experimental diet shown in Table 2 was given, and after rearing for 8 weeks, brown adipose tissue was excised and weighed. The brown adipose tissue weight per body weight of each individual was calculated and evaluated.

褐色脂肪組織重量の結果を表3に示す。パッションフラワー抽出物を与えることで、褐色脂肪組織重量が増加した。すなわち、パッションフラワー抽出物には褐色脂肪組織を増加させる効果があることが示された。 The results of brown adipose tissue weight are shown in Table 3. Feeding passionflower extract increased brown adipose tissue weight. That is, it has been shown that the passionflower extract has an effect of increasing brown adipose tissue.

(実験例3)肥満モデルマウスの褐色脂肪細胞におけるUCP1増加作用の検討
実験例2と同様の方法にて採取した褐色脂肪組織を用いて、遺伝子発現解析及び免疫染色を行った。遺伝子発現解析は、褐色脂肪細胞で発現するUCP1、PGC1α、CIDEA、PDK4の遺伝子発現変動をリアルタイムPCR法で評価した。対照群を1とした遺伝子発現量比を算出した。免疫染色ではAnti−UCP1(CALBIOCHEM)を用いて赤色の蛍光で染色して、タンパク質量を評価した。
(Experimental Example 3) Examination of UCP1 Increasing Effect on Brown Adipocytes of Obese Model Mice Gene expression analysis and immunostaining were performed using brown adipose tissue collected in the same manner as in Experimental Example 2. Gene expression analysis evaluated gene expression fluctuation of UCP1, PGC1α, CIDEA, PDK4 expressed in brown fat cells by real-time PCR. The ratio of gene expression was calculated using the control group as 1. The amount of protein was evaluated by staining with red fluorescence using Anti-UCP1 (CALBIOCHEM) for immunostaining.

褐色脂肪細胞発現遺伝子の発現量比の結果を表4に示す。肥満モデルマウスにパッションフラワー抽出物を与えることで、褐色脂肪組織におけるUCP1、PGC1α、CIDEA、PDK4の遺伝子発現が亢進した。免疫染色では、パッションフラワー抽出物を与えることで、UCP1を染色した赤色の蛍光強度が増加していたことから、褐色脂肪細胞のUCP1タンパク質が増加したといえる。すなわち、パッションフラワー抽出物には褐色脂肪細胞のUCP1を増加させる効果があることが示された。 The results of the expression ratio of brown fat cell expressed genes are shown in Table 4. Feeding passionflower extract to obese model mice enhanced the gene expression of UCP1, PGC1α, CIDEA and PDK4 in brown adipose tissue. In immunostaining, since the fluorescence intensity of the red stained UCP1 was increased by giving the passionflower extract, it can be said that UCP1 protein of brown fat cells increased. That is, it was shown that the passion flower extract has an effect of increasing UCP1 of brown fat cells.

(実験例4)白色脂肪細胞におけるUCP1増加作用の検討
実験例1と同様の方法にてヒト皮下脂肪組織由来幹細胞を白色脂肪細胞へと分化させた。次いで、パッションフラワー抽出物を0.75mg/mLとなるように溶解させた細胞維持培地(10% ウシ胎児血清(SIGMA)、10μg/mL insulin(SIGMA)、33μM biotin(SIGMA)、1% Antibiotic,Antimycotic(GIBCO)となるように添加したDMEM(SIGMA)培地)に置換してから4日間培養し、遺伝子発現解析及び免疫染色を行った。遺伝子発現解析は、褐色脂肪細胞で発現するUCP1、PGC1α、CIDEA、PDK4の遺伝子発現変動をリアルタイムPCR法で評価した。対照群を1とした遺伝子発現量比を算出した。免疫染色ではAnti−UCP1(CALBIOCHEM)を用いて赤色の蛍光で染色して、タンパク質量を評価した。
(Experimental Example 4) Examination of UCP1 Increasing Action in White Adipocytes Human subcutaneous adipose tissue-derived stem cells were differentiated into white adipocytes in the same manner as in Experimental Example 1. Then, cell maintenance medium (passion flour extract was dissolved to 0.75 mg / mL (10% fetal bovine serum (SIGMA), 10 μg / mL insulin (SIGMA), 33 μM biotin (SIGMA), 1% Antibiotic, After replacing with DMEM (SIGMA) medium added to become Antimycotic (GIBCO), the cells were cultured for 4 days, and gene expression analysis and immunostaining were performed. Gene expression analysis evaluated gene expression fluctuation of UCP1, PGC1α, CIDEA, PDK4 expressed in brown fat cells by real-time PCR. The ratio of gene expression was calculated using the control group as 1. The amount of protein was evaluated by staining with red fluorescence using Anti-UCP1 (CALBIOCHEM) for immunostaining.

褐色脂肪細胞発現遺伝子の発現量比の結果を表5に示す。パッションフラワー抽出物を添加することで、白色脂肪細胞に分化させた細胞におけるUCP1、PGC1α、CIDEA、PDK4の遺伝子発現が亢進した。免疫染色では、パッションフラワー抽出物を添加することで、UCP1を染色した赤色の蛍光強度が増加していたことから、UCP1タンパク質が増加したといえる。すなわち、パッションフラワー抽出物には白色脂肪細胞のUCP1を増加させる効果があることが示された。 The results of the expression ratio of brown fat cell expressed genes are shown in Table 5. The addition of passionflower extract enhanced the gene expression of UCP1, PGC1α, CIDEA and PDK4 in cells differentiated into white adipocytes. In immunostaining, it is possible to say that UCP1 protein was increased because addition of the passionflower extract increased the fluorescence intensity of red stained UCP1. That is, it was shown that the passionflower extract has an effect of increasing UCP1 of white fat cells.

(実験例5)肥満モデルマウスの白色脂肪細胞におけるUCP1増加作用の検討
実験例2と同様の方法で飼育したマウスから鼠径部白色脂肪組織を採取して、遺伝子発現解析及び免疫染色を行った。遺伝子発現解析は、UCP1の遺伝子発現変動をリアルタイムPCR法で評価した。対照群を1とした遺伝子発現量比を算出した。免疫染色ではAnti−UCP1(CALBIOCHEM)を用いて赤色の蛍光で染色して、タンパク質量を評価した。
(Experimental Example 5) Examination of UCP1 Increasing Effect on White Adipocytes of Obese Model Mice Inguinal white adipose tissue was collected from a mouse bred by the same method as in Experimental Example 2, and gene expression analysis and immunostaining were performed. Gene expression analysis evaluated the gene expression change of UCP1 by the real-time PCR method. The ratio of gene expression was calculated using the control group as 1. The amount of protein was evaluated by staining with red fluorescence using Anti-UCP1 (CALBIOCHEM) for immunostaining.

褐色脂肪細胞発現遺伝子の発現量比の結果を表6に示す。肥満モデルマウスにパッションフラワー抽出物を与えることで、白色脂肪組織におけるUCP1の遺伝子発現が亢進した。免疫染色では、パッションフラワー抽出物を与えることで、UCP1を染色した赤色の蛍光強度が増加していたことから、白色脂肪細胞のUCP1タンパク質が増加したといえる。すなわち、パッションフラワー抽出物には白色脂肪細胞のUCP1を増加させる効果があることが示された。 The results of the expression ratio of brown fat cell expressed genes are shown in Table 6. Feeding passionflower extract to obese model mice enhanced UCP1 gene expression in white adipose tissue. In immunostaining, since the fluorescence intensity of the red stained UCP1 was increased by providing the passionflower extract, it can be said that the UCP1 protein of white fat cells was increased. That is, it was shown that the passionflower extract has an effect of increasing UCP1 of white fat cells.

(試験例6)低体温改善作用の検討
深部体温が低めの男女計20名(口腔温35.9〜36.1℃)を10名ずつ口腔温の平均値が等しくなるように試験群1、試験群2に分け、試験群1にはパッションフラワー30%エタノール抽出物を含有する飲料(実施例1)、試験群2には従来の飲料(比較例1)を用いて、1日1回100mLを1ヶ月間摂取させた。試験前後に口腔温を体温計により測定した。
(Test Example 6) Examination of hypothermia improvement action Test group 1 so that the average value of the oral temperature becomes equal for every 10 men and women (oral temperature 35.9 to 36.1 ° C.) with lower deep body temperature, which is lower. The test group 2 is divided into a test group 1 using a beverage containing 30% ethanol extract of passionflower (Example 1), and a test group 2 using a conventional beverage (Comparative Example 1), 100 mL once a day Was ingested for 1 month. The oral temperature was measured with a thermometer before and after the test.

試験前後の口腔温を表7に示す。比較例1の飲用前後では変化がないが、実施例1の飲用前後では口腔温が上昇した。すなわち、パッションフラワー抽出物には深部体温を上昇させることで低体温を改善させる効果があることが示された。なお、試験期間中、体調を崩した被験者は一人もなく、安全性においても問題なかった。また、処方成分の劣化についても問題なかった。 The oral temperatures before and after the test are shown in Table 7. Although there was no change before and after drinking in Comparative Example 1, the oral temperature increased before and after drinking in Example 1. That is, it has been shown that the passionflower extract has an effect of improving hypothermia by raising core body temperature. During the trial, there was no subject who got ill, and there was no problem in safety. In addition, there was no problem with the deterioration of prescription ingredients.

また、飲料(実施例1)の代わりに、飲料(実施例2)、軟カプセル剤(実施例3)を1日4粒、硬カプセル剤(実施例4)を1日4粒、錠剤(実施例5)を1日3粒摂取した場合も同様の効果が認められた。 Also, instead of the beverage (Example 1), a beverage (Example 2), 4 soft capsules (Example 3) per day, 4 hard capsules (Example 4) per day, tablets (implementation The same effect was observed when 3 tablets of Example 5) were ingested daily.

本発明は、パッションフラワー抽出物を含有することを特徴とする脂肪燃焼促進剤及び低体温改善剤に関する。よって、肥満、メタボリックシンドローム、低体温の改善及び予防を目的とする医薬品、医薬部外品、食品等に有用である。
The present invention relates to a fat combustion promoter and a hypothermia improving agent characterized by containing passionflower extract. Therefore, it is useful for medicines, quasi-drugs, foods, etc. for the purpose of improvement and prevention of obesity, metabolic syndrome and hypothermia.

Claims (1)

パッションフラワー全草の、エタノール濃度が30〜60%である含水エタノール抽出物を、白色脂肪細胞における脱共役タンパク質1(UCP1)増加剤として含有する低体温改善剤。

The hypothermia improving agent which contains the hydrous ethanol extract whose ethanol concentration is 30 to 60% of passionflower whole grass as an uncoupling protein 1 (UCP1) increase agent in white fat cells .

JP2015001275A 2015-01-07 2015-01-07 Fat burning promoter and hypothermia improving agent Active JP6513404B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2015001275A JP6513404B2 (en) 2015-01-07 2015-01-07 Fat burning promoter and hypothermia improving agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015001275A JP6513404B2 (en) 2015-01-07 2015-01-07 Fat burning promoter and hypothermia improving agent

Publications (2)

Publication Number Publication Date
JP2016124842A JP2016124842A (en) 2016-07-11
JP6513404B2 true JP6513404B2 (en) 2019-05-15

Family

ID=56357452

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015001275A Active JP6513404B2 (en) 2015-01-07 2015-01-07 Fat burning promoter and hypothermia improving agent

Country Status (1)

Country Link
JP (1) JP6513404B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6909569B2 (en) * 2016-09-16 2021-07-28 オリザ油化株式会社 Skin quality improver

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4524022B2 (en) * 2000-05-29 2010-08-11 沖縄食糧株式会社 α-Amylase inhibitor
JP2009054504A (en) * 2007-08-29 2009-03-12 Sumitomo Wiring Syst Ltd Terminal fittings
JP5819209B2 (en) * 2012-01-24 2015-11-18 日本メナード化粧品株式会社 Differentiation promoter from stem cells to brown adipocytes
FR2999429B1 (en) * 2012-12-18 2015-01-02 Expanscience Lab EXTRACT OF PASSIFLORE SEEDS AND COSMETIC, PHARMACEUTICAL, DERMATOLOGICAL OR NUTRACEUTICAL COMPOSITIONS COMPRISING SAME
JP2014156483A (en) * 2014-05-23 2014-08-28 Pola Chem Ind Inc Expression promoter for heat-producing protein

Also Published As

Publication number Publication date
JP2016124842A (en) 2016-07-11

Similar Documents

Publication Publication Date Title
KR101944985B1 (en) Composition for differentiating muscle stem cell to muscle cell, pharmaceutical composition for preventing or treating muscle weakness diseases and health functional food composition for enhancing exercise capacity comprising Lithospermum erythrorhizon extract
CN105722519A (en) Composition containing a borage officinalis extract for alleviating, preventing, or treating metabolic diseases
JP6281741B2 (en) Muscle cell activator
JP4764518B1 (en) Oral pore improver
TW201813656A (en) Composition for changing the expression of a clock gene capable of making the subject having changes that the afternoon drowsiness is decreased, the lucidity, will, mood and concentration ability are increased, and early morning tendency becomes stronger
KR101392715B1 (en) A composotion for the treatment of obesity comprising the coicis semen complex
JP5819209B2 (en) Differentiation promoter from stem cells to brown adipocytes
KR20160141027A (en) Phamaceutical composition or healthy food comprising water extracts from Pleurotus eryngii var. ferulea (Pf.). for treating or preventing metabolic disorder
KR20160099963A (en) Pharmaceutical composition for prevention or treatment of obesity comprising the extracts of Schizandra chinensis as active ingredient
JP6513404B2 (en) Fat burning promoter and hypothermia improving agent
JP7229513B2 (en) Brain function improving agent and food and drink for improving brain function
KR101735061B1 (en) Composition containing Artemisia annua extract, artemisinin or dihydroartemisinin for preventing or treating obesity
KR101913828B1 (en) Composition for differentiating muscle stem cell to muscle cell, pharmaceutical composition for preventing or treating muscle weakness diseases and health functional food composition for enhancing exercise capacity comprising Lithospermum erythrorhizon extract
JP6964290B2 (en) ATP production promoting agent
KR20160049216A (en) Composition comprising carnosic acid for preventing or improving menopausal symptoms
KR101732146B1 (en) Composition for anti-obesity with the extract of corn silk and Poncirus trifoliata
JP2014185088A (en) Oral composition, adipocyte differentiation inhibitor, and food and drink
KR20180106105A (en) Composition for antiinflammatory and inflammatory neurodegenerative diseases comprising lycium barbarum extract
JP2012025717A (en) Oral climacteric symptom improvement agent
JP6462755B2 (en) Brain function improving agent and food and drink for improving brain function
KR102121573B1 (en) Composition for preventing, treating or improving obesity comprising Jaceosidin
KR20200116783A (en) Composition for preventing or treating andropause related symptoms comprising the extract of rice straw
KR102514847B1 (en) Composition for preventing or treating cognitive dysfunction or neuroinflammation comprising extracts of centella asiatica, cnidium monnieri, and lycium barbarum linne
JP6204019B2 (en) CGI-58 expression promoter
JP2009126790A (en) Bloodstream-improving agent, and food and drink containing the same

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190410

R150 Certificate of patent or registration of utility model

Ref document number: 6513404

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250